309 related articles for article (PubMed ID: 23487168)
21. Do all angiotensin II type 1 receptor blockers have the same beneficial effects?
Miura S; Saku K
Br J Pharmacol; 2007 Aug; 151(7):912-3. PubMed ID: 17572701
[TBL] [Abstract][Full Text] [Related]
22. Long-lasting angiotensin type 1 receptor binding and protection by candesartan: comparison with other biphenyl-tetrazole sartans.
Vauquelin G; Fierens F; Van Liefde I
J Hypertens Suppl; 2006 Mar; 24(1):S23-30. PubMed ID: 16601569
[TBL] [Abstract][Full Text] [Related]
23. Comparative assessment of angiotensin receptor blockers in different clinical settings.
Verdecchia P; Angeli F; Repaci S; Mazzotta G; Gentile G; Reboldi G
Vasc Health Risk Manag; 2009; 5():939-48. PubMed ID: 19997575
[TBL] [Abstract][Full Text] [Related]
24. Angiotensin II type 1 receptor blockade: high hopes sent back to reality?
Grothusen A; Divchev D; Luchtefeld M; Schieffer B
Minerva Cardioangiol; 2009 Dec; 57(6):773-85. PubMed ID: 19942847
[TBL] [Abstract][Full Text] [Related]
25. Nanotechnology-Based Strategies for Extended-Release Delivery of Angiotensin Receptor Blockers (ARBs): A Comprehensive Review.
Haji Ali B; Shirvaliloo M; Fathi-Karkan S; Mirinejad S; Ulucan-Karnak F; Sargazi S; Sargazi S; Sheervalilou R; Rahman MM
Chem Biodivers; 2023 Nov; 20(11):e202301157. PubMed ID: 37796134
[TBL] [Abstract][Full Text] [Related]
26. In vitro antagonistic properties of a new angiotensin type 1 receptor blocker, azilsartan, in receptor binding and function studies.
Ojima M; Igata H; Tanaka M; Sakamoto H; Kuroita T; Kohara Y; Kubo K; Fuse H; Imura Y; Kusumoto K; Nagaya H
J Pharmacol Exp Ther; 2011 Mar; 336(3):801-8. PubMed ID: 21123673
[TBL] [Abstract][Full Text] [Related]
27. Reassessment of the unique mode of binding between angiotensin II type 1 receptor and their blockers.
Miura S; Nakao N; Hanzawa H; Matsuo Y; Saku K; Karnik SS
PLoS One; 2013; 8(11):e79914. PubMed ID: 24260317
[TBL] [Abstract][Full Text] [Related]
28. [Tendency and prospect of the development of new ARBs].
Kim S
Nihon Rinsho; 2002 Oct; 60(10):1881-6. PubMed ID: 12397678
[TBL] [Abstract][Full Text] [Related]
29. Concentration-dependent mode of interaction of angiotensin II receptor blockers with uric acid transporter.
Iwanaga T; Sato M; Maeda T; Ogihara T; Tamai I
J Pharmacol Exp Ther; 2007 Jan; 320(1):211-7. PubMed ID: 17043154
[TBL] [Abstract][Full Text] [Related]
30. A review of the current evidence for the use of angiotensin-receptor blockers in chronic heart failure.
Erhardt LR
Int J Clin Pract; 2005 May; 59(5):571-8. PubMed ID: 15857354
[TBL] [Abstract][Full Text] [Related]
31. [The role of angiotensin II AT1-receptor antagonists in renal and cardiac protection in type-2 diabetes mellitus].
Ravera M; Deferrari L; Ratto E; Vettoretti S; Parodi D; Deferrari G
Ital Heart J Suppl; 2003 Mar; 4(3):210-6. PubMed ID: 12784755
[TBL] [Abstract][Full Text] [Related]
32. Losartan in diabetic nephropathy.
Perico N; Ruggenenti P; Remuzzi G
Expert Rev Cardiovasc Ther; 2004 Jul; 2(4):473-83. PubMed ID: 15225108
[TBL] [Abstract][Full Text] [Related]
33. Differential effects of angiotensin II receptor blockers on Aβ generation.
Liu J; Liu S; Tanabe C; Maeda T; Zou K; Komano H
Neurosci Lett; 2014 May; 567():51-6. PubMed ID: 24680748
[TBL] [Abstract][Full Text] [Related]
34. Clinical experience with the use of angiotensin receptor blockers in patients with cardiovascular, cerebrovascular and renal diseases.
Chrysant SG
Curr Clin Pharmacol; 2006 May; 1(2):139-46. PubMed ID: 18666366
[TBL] [Abstract][Full Text] [Related]
35. Current topics in angiotensin II type 1 receptor research: Focus on inverse agonism, receptor dimerization and biased agonism.
Takezako T; Unal H; Karnik SS; Node K
Pharmacol Res; 2017 Sep; 123():40-50. PubMed ID: 28648738
[TBL] [Abstract][Full Text] [Related]
36. Therapeutic effects of angiotensin (AT1) receptor antagonists: potential contribution of mechanisms other than AT1 receptor blockade.
Schmidt B; Drexler H; Schieffer B
Am J Cardiovasc Drugs; 2004; 4(6):361-8. PubMed ID: 15554721
[TBL] [Abstract][Full Text] [Related]
37. Analysis of published economic evaluations of angiotensin receptor blockers.
Theodoratou D; Maniadakis N; Fragoulakis V; Stamouli E
Hellenic J Cardiol; 2009; 50(2):105-18. PubMed ID: 19329412
[TBL] [Abstract][Full Text] [Related]
38. Use of Angiotensin receptor blockers in cardiovascular protection: current evidence and future directions.
Munger MA
P T; 2011 Jan; 36(1):22-40. PubMed ID: 21386934
[TBL] [Abstract][Full Text] [Related]
39. Photosensitivity with Angiotensin II Receptor Blockers: A Retrospective Study Using Data from VigiBase(®).
Viola E; Coggiola Pittoni A; Drahos A; Moretti U; Conforti A
Drug Saf; 2015 Oct; 38(10):889-94. PubMed ID: 26187686
[TBL] [Abstract][Full Text] [Related]
40. Olmesartan is More Effective Than Other Angiotensin Receptor Antagonists in Reducing Proteinuria in Patients With Chronic Kidney Disease Other Than Diabetic Nephropathy.
Ono T; Sanai T; Miyahara Y; Noda R
Curr Ther Res Clin Exp; 2013 Jun; 74():62-7. PubMed ID: 24384547
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
